03.04.24 -- Tracking 4 Payload Trends In Drug Delivery Development

Alongside the great promise of mRNA vaccine development comes a list of unique challenges to overcome. Researchers are tackling these challenges while striving for a shorter time to market.

Learn how a CDMO with a commitment to quality and decades of industry experience can help overcome development hurdles and bring your treatment to patients in need.

The need for a single platform that assists EV manufacturers in meeting necessary criteria is driving technology innovations, including work on structured fixed-bed bioreactors.

Characterization and comparison of originator and biosimilar candidate mAbs is challenging due to their complex and variable structures, resulting in the need for a range of analytical techniques.

Review this demonstration of a bioreactor and bioreactor system combination used to isolate exosomes after culturing human adipose-derived stem cells in suspension on microcarriers.

Dissect the reasons for capacity bottlenecks stemming from process development scope, downstream chromatography, and equipment constraints, and delve into the potential solutions associated with each.

Impurities from IVT can induce undesired immune responses and negatively impact translation efficiency. Explore the pros and cons of each option for mRNA purification.

Drug product stability may be seriously compromised if mannitol completes crystallization during storage rather than during the freezing or annealing step in the lyophilization process.

In this webinar, Dr. Colette Quinn discusses the use of differential scanning calorimetry (DSC) in protein stability characterization differences resulting from preparation changes of identical systems.

Learn about the growing role of CDMOs in supporting the development of advanced analytics products, including mass spectrometry, and how to optimize the analyte life cycle.

Packaging is critical, as biotechnology products requiring colder storage become more valuable. Find out how you can improve your temperature-controlled supply chain and meet cold chain storage demands.

Review a scalable suspension-based Lenti production platform using a proprietary HEK293T clonal cell line and improvement steps to generate commercially viable therapies from concept to patient.

Join experts for an in-depth look at novel techniques to reduce process and hold steps, downstream process innovations, and more, backed by study results.

Explore how some drug manufacturers are using the latest computer software assurance (CSA) guidance to reduce effort and cost and the bumps you may hit along the way.